BioCryst Pharmaceuticals (BioCryst Pharmaceuticals) Price-to-Operating-Cash-Flow : (As of Apr. 27, 2024)

View and export this data going back to 1994. Start your Free Trial

What is BioCryst Pharmaceuticals Price-to-Operating-Cash-Flow?

As of today (2024-04-27), BioCryst Pharmaceuticals's share price is $4.16. BioCryst Pharmaceuticals's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.50. Hence, BioCryst Pharmaceuticals's Price-to-Operating-Cash-Flow Ratio for today is .

The historical rank and industry rank for BioCryst Pharmaceuticals's Price-to-Operating-Cash-Flow or its related term are showing as below:

BCRX's Price-to-Operating-Cash-Flow is not ranked ^*
in the Biotechnology industry.
Industry Median: 24.725
* Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.

BioCryst Pharmaceuticals's Cash Flow from Operations per share for the three months ended in Dec. 2023 was $-0.04. Its Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.50.

During the past 3 years, the average Operating Cash Flow per Share Growth Rate was 15.10% per year. During the past 5 years, the average Operating Cash Flow per Share Growth Rate was 7.30% per year. During the past 10 years, the average Operating Cash Flow per Share Growth Rate was -6.50% per year.

During the past 13 years, BioCryst Pharmaceuticals's highest 3-Year average Operating Cash Flow per Share Growth Rate was 39.20% per year. The lowest was -70.80% per year. And the median was 4.00% per year.

BioCryst Pharmaceuticals Price-to-Operating-Cash-Flow Historical Data

The historical data trend for BioCryst Pharmaceuticals's Price-to-Operating-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioCryst Pharmaceuticals Price-to-Operating-Cash-Flow Chart

BioCryst Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Price-to-Operating-Cash-Flow

Get a 7-Day Free Trial

BioCryst Pharmaceuticals Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Price-to-Operating-Cash-Flow	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of BioCryst Pharmaceuticals's Price-to-Operating-Cash-Flow

For the Biotechnology subindustry, BioCryst Pharmaceuticals's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BioCryst Pharmaceuticals's Price-to-Operating-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioCryst Pharmaceuticals's Price-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where BioCryst Pharmaceuticals's Price-to-Operating-Cash-Flow falls into.

BioCryst Pharmaceuticals Price-to-Operating-Cash-Flow Calculation

BioCryst Pharmaceuticals's Price-to-Operating-Cash-Flow ratio for today is calculated as

Price-to-Operating-Cash-Flow Ratio	=	Share Price	/	Cash Flow from Operations per share (TTM)
	=	4.16	/	-0.5
	=

BioCryst Pharmaceuticals's Share Price of today is $4.16.
BioCryst Pharmaceuticals's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.50.

Note: Cash Flow from Operations per share is calculated as Cash Flow from Operations divided by Shares Outstanding (Diluted Average).

It can also be calculated from the numbers for the whole company:

Price-to-Operating-Cash-Flow Ratio

Market Cap

Cash Flow from Operations

BioCryst Pharmaceuticals Price-to-Operating-Cash-Flow Related Terms

Thank you for viewing the detailed overview of BioCryst Pharmaceuticals's Price-to-Operating-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.

BioCryst Pharmaceuticals (BioCryst Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioCryst Pharmaceuticals Inc (NAS:BCRX) » Definitions » Price-to-Operating-Cash-Flow

Comparable Companies

Traded in Other Exchanges

BCRX:Mexico BO1:Germany BO1:Germany

Address

4505 Emperor Boulevard, Suite 200, Durham, NC, USA, 27703

Website

http://www.biocryst.com

BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, with the aim of blocking key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.

Executives

Machelle Sanders	director	C/O NOVAN, INC., 4105 HOPSON ROAD, MORRISVILLE NC 27560
Nancy J Hutson	director	64 MONTAUK AVENUE, STONINGTON CT 06378
Helen M. Thackray	director	C/O GLYCOMIMETICS, INC., 401 PROFESSIONAL DRIVE, SUITE 250, GAITHERSBURG MD 20879
Jon P Stonehouse	director, officer: CEO	2190 PARKWAY LAKE DR, BIRMINGHAM AL 35244
Charles K Gayer	officer: Vice President and CCO	4505 EMPEROR BLVD., SUITE 200, DURHAM NC 27703
Michael L Jones	officer: Exec Director, Finance - PAO	4505 EMPEROR BLVD., SUITE 200, DURHAM NC 27703
Alane P Barnes	officer: VP, General Counsel & Corp Sec	1929 BRASSFIELD ROAD, RALEIGH NC 27614
Anthony Doyle	officer: Chief Financial Officer	4505 EMPEROR BLVD., SUITE 200, DURHAM NC 27703
Yarlagadda S Babu	officer: VP Drug Discovery	2190 PARKWAY LAKE DR, BIRMINGHAM AL 35244
George B Abercrombie	director	C/O INSPIRE PHARMACEUTICALS, INC., 4222 EMPEROR BLVD., SUITE 200, DURHAM NC 27703
William P Sheridan	officer: SR VP - CMO	2190 PARKWAY LAKE DR, BIRMINGHAM AL 35244
Vincent Milano	director	C/O VIROPHARMA INC, 405 EAGLEVIEW BLVD, EXTON PA 19341
Amy E Mckee	director	4505 EMPEROR BLVD, SUITE 200, DURHAM NC 27703
Lee Kenneth B Jr	director	7100 WEST CREDIT AVENUE, SUITE 101, C/O ARALEZ PHARMACEUTICALS INC., MISSISSAUGA A6 L5N 0E4
Steven K Galson	director	C/O BIOCRYST PHARMACEUTICALS, INC., 4505 EMPEROR BLVD, SUITE 200, DURHAM NC 27703